Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial — Víctor Pérez (2017) | RDL Network
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
Article 2017 en
Authors
VP
Víctor Pérez
AS
Ariana Salavert
JE
Jordi Espadaler
Abstract
1 min read
European Clinical Trials Database 2013-002228-18 , registration date September 16, 2013; ClinicalTrials.gov NCT02529462 , retrospectively registered: August 19, 2015.
Anna J. Podolanczuk, John S. Kim, Christopher B. Cooper, Joseph A. Lasky, Susan Murray, Justin M. Oldham, Ganesh Raghu, Kevin R. Flaherty, Cathie Spino, Imre Noth, Fernando J. Martínez, Elizabeth Freiheit, Adam Martin‐Schwarze, Ashley Szparza, Tanvi Naik, Rex Edwards, Gordon R. Bernard, Deborah R. Barnbaum, João A. de Andrade, Daren L. Knoell, Peter K. Lindenauer, André Rogatko, Marinella Temprosa,
Crick Lund, Marguerite Schneider, Thandi Davies, Memory Nyatsanza, Simone Honikman, Arvin Bhana, Judith Bass, Paul Bolton, Michael Dewey, John A. Joska, Ashraf Kagee, Landon Myer, Inge Petersen, Martin Prince, Dan Joseph Stein, Graham Thornicroft, Mark Tomlinson, Atalay Alem, Ezra Susser
Lew Lim, Nazanin Hosseinkhah, Mark Van Buskirk, Andrea Berk, Genane Loheswaran, Zara Abbaspour, Mahta Karimpoor, Alison Smith, Kai Fai Ho, Abhiram Pushparaj, Michael Zahavi, Alexander White, Jonathan Rubine, Brian Zidel, Christopher Henderson, Russell Gene Clayton, David Roy Tingley, David Miller, Mahroo Karimpoor, Michael R Hamblin
Discussion(0)
No comments yet. Be the first to comment.